Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests.

Georghiou SB, Schumacher SG, Rodwell TC, Colman RE, Miotto P, Gilpin C, Ismail N, Rodrigues C, Warren R, Weyer K, Zignol M, Arafah S, Cirillo DM, Denkinger CM.

J Infect Dis. 2019 Oct 8;220(Supplement_3):S126-S135. doi: 10.1093/infdis/jiz106.

PMID:
31593599
2.

Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis.

Drain PK, Gardiner J, Hannah H, Broger T, Dheda K, Fielding K, Walzl G, Kaforou M, Kranzer K, Joosten SA, Gilpin C, Weyer K, Denkinger CM, Schumacher SG.

J Infect Dis. 2019 Oct 8;220(Supplement_3):S108-S115. doi: 10.1093/infdis/jiz356.

PMID:
31593598
3.

Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis.

Schumacher SG, Wells WA, Nicol MP, Steingart KR, Theron G, Dorman SE, Pai M, Churchyard G, Scott L, Stevens W, Nabeta P, Alland D, Weyer K, Denkinger CM, Gilpin C.

J Infect Dis. 2019 Oct 8;220(Supplement_3):S99-S107. doi: 10.1093/infdis/jiz258.

PMID:
31593597
4.

Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles.

Denkinger CM, Schumacher SG, Gilpin C, Korobitsyn A, Wells WA, Pai M, Leeflang M, Steingart KR, Bulterys M, Schünemann H, Glaziou P, Weyer K.

J Infect Dis. 2019 Oct 8;220(Supplement_3):S91-S98. doi: 10.1093/infdis/jiz097.

PMID:
31593596
5.

Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.

Hinrichs GR, Weyer K, Friis UG, Svenningsen P, Lund IK, Nielsen R, Mollet G, Antignac C, Bistrup C, Jensen BL, Birn H.

Acta Physiol (Oxf). 2019 Aug 19:e13362. doi: 10.1111/apha.13362. [Epub ahead of print]

PMID:
31423748
6.

Mutual Facilitation Among Invading Nuttall's Waterweed and Quagga Mussels.

Wegner B, Kronsbein AL, Gillefalk M, van de Weyer K, Köhler J, Funke E, Monaghan MT, Hilt S.

Front Plant Sci. 2019 Jun 26;10:789. doi: 10.3389/fpls.2019.00789. eCollection 2019.

7.

APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.

Tachibana M, Holm ML, Liu CC, Shinohara M, Aikawa T, Oue H, Yamazaki Y, Martens YA, Murray ME, Sullivan PM, Weyer K, Glerup S, Dickson DW, Bu G, Kanekiyo T.

J Clin Invest. 2019 Mar 1;129(3):1272-1277. doi: 10.1172/JCI124853. Epub 2019 Feb 11.

8.

The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.

Falzon D, Jaramillo E, Gilpin C, Weyer K.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S365-S367. doi: 10.1093/cid/ciy710. No abstract available.

9.

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.

Weyer K, Falzon D, Jaramillo E.

Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230. No abstract available.

10.

Inclusion of TB diagnostics on the WHO Essential Diagnostics List.

Gilpin C, Weyer K.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):827-828. doi: 10.5588/ijtld.18.0371. No abstract available.

PMID:
29991385
11.

Priorities for global political momentum to end TB: a critical point in time.

Kasaeva T, Baddeley A, Floyd K, Jaramillo E, Lienhardt C, Nishikiori N, Weil DE, Weyer K, Zignol M.

BMJ Glob Health. 2018 Mar 23;3(2):e000830. doi: 10.1136/bmjgh-2018-000830. eCollection 2018. No abstract available.

12.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

13.

The Authors Reply.

Weyer K, Birn H, Nielsen R, Christensen EI.

Kidney Int. 2018 Apr;93(4):1014-1015. doi: 10.1016/j.kint.2018.01.006. No abstract available.

PMID:
29571436
14.

The World Health Organization standards for tuberculosis care and management.

Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800098. doi: 10.1183/13993003.00098-2018. Print 2018 Mar. No abstract available.

15.

The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.

Halleux CM, Falzon D, Merle C, Jaramillo E, Mirzayev F, Olliaro P, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1701643. doi: 10.1183/13993003.01643-2017. Print 2018 Mar. No abstract available.

16.

Fungaemia caused by obstructive renal candida bezoars leads to bilateral chorioretinitis: a case report.

Stein J, Latz S, Ellinger J, Fechner G, Safi M, Krausewitz P, Müller S, Weyer K, Müller SC.

BMC Urol. 2018 Mar 16;18(1):21. doi: 10.1186/s12894-018-0335-6.

17.

Response of Submerged Macrophyte Communities to External and Internal Restoration Measures in North Temperate Shallow Lakes.

Hilt S, Alirangues Nuñez MM, Bakker ES, Blindow I, Davidson TA, Gillefalk M, Hansson LA, Janse JH, Janssen ABG, Jeppesen E, Kabus T, Kelly A, Köhler J, Lauridsen TL, Mooij WM, Noordhuis R, Phillips G, Rücker J, Schuster HH, Søndergaard M, Teurlincx S, van de Weyer K, van Donk E, Waterstraat A, Willby N, Sayer CD.

Front Plant Sci. 2018 Feb 19;9:194. doi: 10.3389/fpls.2018.00194. eCollection 2018.

18.

Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.

Falzon D, Migliori GB, Jaramillo E, Weyer K, Joos G, Raviglione M; Global Task Force on digital health for TB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701632. doi: 10.1183/13993003.01632-2017. Print 2017 Nov. No abstract available.

19.

Abolishment of proximal tubule albumin endocytosis does not affect plasma albumin during nephrotic syndrome in mice.

Weyer K, Andersen PK, Schmidt K, Mollet G, Antignac C, Birn H, Nielsen R, Christensen EI.

Kidney Int. 2018 Feb;93(2):335-342. doi: 10.1016/j.kint.2017.07.024. Epub 2017 Oct 14.

PMID:
29032953
20.

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.

Gustafsen C, Olsen D, Vilstrup J, Lund S, Reinhardt A, Wellner N, Larsen T, Andersen CBF, Weyer K, Li JP, Seeberger PH, Thirup S, Madsen P, Glerup S.

Nat Commun. 2017 Sep 11;8(1):503. doi: 10.1038/s41467-017-00568-7.

21.

Megalin dependent urinary cystatin C excretion in ischemic kidney injury in rats.

Jensen D, Kierulf-Lassen C, Kristensen MLV, Nørregaard R, Weyer K, Nielsen R, Christensen EI, Birn H.

PLoS One. 2017 Jun 2;12(6):e0178796. doi: 10.1371/journal.pone.0178796. eCollection 2017.

22.

Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.

Falzon D, Jaramillo E, Gilpin C, Weyer K.

Eur Respir J. 2017 Apr 26;49(4). pii: 1700317. doi: 10.1183/13993003.00317-2017. Print 2017 Apr. No abstract available.

23.

Current tools available for the diagnosis of drug-resistant tuberculosis.

Gilpin C, Korobitsyn A, Weyer K.

Ther Adv Infect Dis. 2016 Dec;3(6):145-151. doi: 10.1177/2049936116673553. Epub 2016 Oct 14. Review.

24.

Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.

Yassin MA, Jaramillo E, Wandwalo E, Falzon D, Scardigli A, Kunii O, Weyer K.

Eur Respir J. 2017 Mar 22;49(3). pii: 1700081. doi: 10.1183/13993003.00081-2017. Print 2017 Mar. No abstract available.

25.

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602308. doi: 10.1183/13993003.02308-2016. Print 2017 Mar.

26.

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC.

N Engl J Med. 2016 Sep 15;375(11):1081-9. doi: 10.1056/NEJMsr1512438. No abstract available.

27.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

28.

Digital health for the End TB Strategy: developing priority products and making them work.

Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC.

Eur Respir J. 2016 Jul;48(1):29-45. doi: 10.1183/13993003.00424-2016. Epub 2016 May 26.

29.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions.

Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AM, Matthiessen L, Mgone CS, Mizrahi V, Mukadi YD, Nguyen VN, Nordström A, Sizemore CF, Spigelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M.

PLoS Med. 2016 Mar 2;13(3):e1001965. doi: 10.1371/journal.pmed.1001965. eCollection 2016 Mar. Review. No abstract available.

30.

False Alarms, Pseudoepidemics, and Reality: A Case Study with American College of Obstetricians and Gynecologists Practice Bulletins.

Chauhan SP, Hammad IA, Weyer KL, Ananth CV.

Am J Perinatol. 2016 Apr;33(5):442-8. doi: 10.1055/s-0035-1566247. Epub 2015 Nov 2. Review.

PMID:
26523741
31.

Comparative test of ecological assessment methods of lowland streams based on long-term monitoring data of macrophytes.

Wiegleb G, Gebler D, van de Weyer K, Birk S.

Sci Total Environ. 2016 Jan 15;541:1269-1281. doi: 10.1016/j.scitotenv.2015.10.005. Epub 2015 Nov 11.

PMID:
26476066
32.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

33.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

34.

Institutional Tuberculosis Transmission. Controlled Trial of Upper Room Ultraviolet Air Disinfection: A Basis for New Dosing Guidelines.

Mphaphlele M, Dharmadhikari AS, Jensen PA, Rudnick SN, van Reenen TH, Pagano MA, Leuschner W, Sears TA, Milonova SP, van der Walt M, Stoltz AC, Weyer K, Nardell EA.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):477-84. doi: 10.1164/rccm.201501-0060OC.

35.

Discovery, innovation, and new frontiers in tuberculosis diagnostics: reflections and expectations.

Weyer K.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S78-80. doi: 10.1093/infdis/jiu822. Review. No abstract available.

PMID:
25765109
36.

Defining the needs for next generation assays for tuberculosis.

Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S29-38. doi: 10.1093/infdis/jiu821. Review.

37.

Tuberculosis control: hard questions.

Weyer K, Falzon D, Wares F, Jaramillo E, Raviglione M.

Lancet. 2014 Nov 15;384(9956):1744. doi: 10.1016/S0140-6736(14)62065-1. Epub 2014 Nov 14. No abstract available.

PMID:
25455240
38.

Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation.

Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC.

Eur Respir J. 2014 Dec;44(6):1412-7. doi: 10.1183/09031936.00132114. No abstract available.

39.

Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M.

Eur Respir J. 2015 Jan;45(1):150-60. doi: 10.1183/09031936.00101814. Epub 2014 Sep 26.

40.

Papp-a2 modulates development of cranial cartilage and angiogenesis in zebrafish embryos.

Kjaer-Sorensen K, Engholm DH, Jepsen MR, Morch MG, Weyer K, Hefting LL, Skov LL, Laursen LS, Oxvig C.

J Cell Sci. 2014 Dec 1;127(Pt 23):5027-37. doi: 10.1242/jcs.152587. Epub 2014 Sep 18.

41.

Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.

Gao S, Hein S, Dagnæs-Hansen F, Weyer K, Yang C, Nielsen R, Christensen EI, Fenton RA, Kjems J.

Theranostics. 2014 Aug 13;4(10):1039-51. doi: 10.7150/thno.7866. eCollection 2014.

42.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB.

Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.

43.

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, Nunn P, Jaramillo E, Keshavjee S, Wares DF.

BMJ Open. 2014 Jan 2;4(1):e004143. doi: 10.1136/bmjopen-2013-004143. Review.

44.

Drug-resistant tuberculosis: latest advances.

Falzon D, Weyer K, Raviglione MC.

Lancet Respir Med. 2013 Mar;1(1):e9-e10. doi: 10.1016/S2213-2600(12)70056-5. Epub 2013 Jan 14. No abstract available.

PMID:
24321818
45.

The authors reply.

Nielsen R, Weyer K, Birn H, Christensen EI.

Kidney Int. 2013 Nov;84(5):1050-1. doi: 10.1038/ki.2013.326. No abstract available.

46.

Increased lysosomal proteolysis counteracts protein accumulation in the proximal tubule during focal segmental glomerulosclerosis.

Nielsen R, Mollet G, Esquivel EL, Weyer K, Nielsen PK, Antignac C, Christensen EI.

Kidney Int. 2013 Nov;84(5):902-10. doi: 10.1038/ki.2013.218. Epub 2013 Jun 12.

47.

Linezolid for extensively drug-resistant tuberculosis.

Jaramillo E, Weyer K, Raviglione M.

N Engl J Med. 2013 Jan 17;368(3):290. doi: 10.1056/NEJMc1214183. No abstract available.

PMID:
23323917
48.

Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis.

Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K.

Eur Respir J. 2013 Sep;42(3):708-20. doi: 10.1183/09031936.00147912. Epub 2012 Dec 20.

49.

Renal uptake of 99mTc-dimercaptosuccinic acid is dependent on normal proximal tubule receptor-mediated endocytosis.

Weyer K, Nielsen R, Petersen SV, Christensen EI, Rehling M, Birn H.

J Nucl Med. 2013 Jan;54(1):159-65. doi: 10.2967/jnumed.112.110528. Epub 2012 Dec 11.

50.

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, Floyd K, Centis R, Cirillo DM, Tortoli E, Gilpin C, de Dieu Iragena J, Falzon D, Raviglione M.

Eur Respir J. 2013 Jul;42(1):252-71. doi: 10.1183/09031936.00157212. Epub 2012 Nov 22. Review.

Supplemental Content

Support Center